Division and Department

Department of Comprehensive Cancer


Hiroyuki SHIBATA, M.D. & Ph. D.

A Greeting from the Professor

The Department of Comprehensive Cancer Control was established in 2012 for the purpose of education of the cancer patients and the medical care givers for cancer control in Akita prefecture.

We are focusing on the development of educational tools of the patients as well as the medical professionals.

cares should be estimated by using these clinical data.

Staff

Professor:
Hiroyuki SHIBATA, M.D. & Ph. D.

Research Areas

  1. Supportive care of cancer patients
  2. Development of Educational tool of cancer patients
  3. Development of clinical guideline
  4. Development of remote medical care of cancer patients
  5. Clinical trials

Contact Information

1-1-1 Hondo, Akita, 010-8543, Japan
Phone: +81-18-884-6261/6262
Fax: +81-18-884-6455
E-mail: [email protected](H.S.)

Most Recent Achievements

  1. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. T Yoshida, K Takahashi, K Shibuya, O Muto, Y Yoshida, D Taguchi, K Shimazu, K Fukuda, F Ono, K Nomura, H Shibata. World Journal of Gastrointestinal Oncology 13 (4), 295, 2021
  2. Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution. T Yoshida, D Taguchi, K Fukuda, K Shimazu, M Inoue, K Murata, H Shibata. International journal of clinical oncology 22 (2), 244-249, 2017
  3. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese orthopedic association, Japanese Urological Association, and Japanese Society for Radiation Oncology
    H Shibata, S Kato, I Sekine, K Abe, N Araki, H Iguchi, T Izumi, Y Inaba, I.Osaka, S.Kato, A.Kawai, S.Kinuya, M.Kodaira, E.Kobayashi, T.Kobayashi, J.Sato, N.Shinohara, S.Takahashi, Y.Takamatsu, K.Takayama, K.Takayama, U.Tateishi, H.Nagakura, M.Hosaka, H.Morioka, T.Moriya, T.Yuasa, T.Yurikusa, K.Yomiya, M.Yoshida. ESMO open 1 (2), e000037, 2016
  4. Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. H Imai, H Soeda, K Komine, K Otsuka, H Shibata
    BMC palliative care 12 (1), 1-5, 2013
  5. Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer
    M Kochi, W Ichikawa, E Meguro, H Shibata, T Fukui, M Nagase, Y Hoshino, M Takeuchi, M Fujii, T Nakajima. Cancer chemotherapy and pharmacology 68 (5), 1215-1222, 2011

back